Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

• Published in: Oncology Vol. 89; no. 5; pp. 275 - 280
• Main Authors: Igawa, Satoshi, Sasaki, Jiichiro, Otani, Sakiko, Ishihara, Mikiko, Takakura, Akira, Katagiri, Masato, Masuda, Noriyuki
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2015
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Clinical Study; Development and progression; Disease-Free Survival; Drug therapy; Female; Gefitinib; Gene mutations; Genetic aspects; Health aspects; Humans; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Middle Aged; Mutation - genetics; Patient outcomes; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - genetics; Retrospective Studies; Smoking; Smoking - adverse effects; Treatment Outcome; Japan; Smoking status; Epidermal growth factor receptor mutation; Gefitinib; Predictor; Non-small cell lung cancer

Background: Gefitinib treatment has come to be recognized as the standard therapy for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. However, resistance to gefitinib has been observed in certain subpopulations of these patients. The purp...